Moderna (MRNA) insider buying and selling
Every Table I transaction reported by directors and officers of S&P 500 companies on SEC Form 4 filings (2 business days to file): each row labeled with its official transaction code, nothing filtered out beforehand.
Open-market purchases (code P) are the rare signal, in green; sales (code S) are common and often pre-scheduled (10b5-1). Table II (derivatives) is not included: its prices are exercise prices, not market values. Guide: insider buying.
| Date | Ticker | Insider | Role | Shares | Price | Amount | % of stake | Type / filing |
|---|
Download these transactions as CSV No account, no sign-up. The data is public: it comes from SEC Form 4 filings.
Moderna, Inc. (MRNA) insider buying and selling: no purchases, 17 sales
148 Form 4 Table I transactions filed with the SEC by Moderna, Inc. insiders between 2025-08-29 and 2026-10-16 (15-month history): 0 open-market purchases and 17 sales, plus 131 transactions under other Form 4 codes, broken down one by one below. The largest open-market trade is a sale of $28.7M by Bancel Stephane on 2026-08-05.
Moderna insider buying and selling over the last 12 months
Between Oct 21, 2025 and Oct 20, 2026, Moderna insiders filed 17 sales worth $81.6M on the open market, and no purchases.
The biggest seller was Hoge Stephen (President): $45.4M in 8 sales, out of 6 different sellers.
The largest trade of the period was a sale of $28.7M on Aug 5, 2026, by Bancel Stephane (Chief Executive Officer), under a 10b5-1 plan. Form 4 on sec.gov (0001682852-26-000153).
Of the 17 sales, 15 (88%, $80.5M) carry the 10b5-1 plan flag on the Form 4, meaning they were scheduled months ahead; the other 2 do not.
The last three months show 7 sales, against 6 in the three before. The latest sale from Oct 15, 2026.
Against its sector (Healthcare, 59 companies with an insider page on this site), over the same dates the median is 9 sales and 0 purchases on the open market. Moderna has more sales than 43 of the other 58, ranks 11 of 59 by net dollars sold, and 19 of the 59 have at least one purchase.
The 20 most important trades
With no open-market purchases, the table starts with MRNA's sales, largest first. The full history is in the tool above, already searched.
See all 148 MRNA trades in the full history →
| Trade date | Filed | Insider | Role | Amount | Code | Filing |
|---|---|---|---|---|---|---|
| 2026-08-05 | 2026-08-07 | Bancel Stephane | Chief Executive Officer | $28.7M | S — Open-market sale (scheduled 10b5-1)5 Form 4 footnotesF1 The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026. The Reporting Person exercised in full two stock option awards that were scheduled to expire on August 10, 2026. The options would have been forfeited if not exercised prior to their expiration date. In connection with the cashless exercise and hold transaction, the Reporting Person sold 499,246 shares acquired upon exercise solely to cover the exercise price, applicable withholding taxes, and related transaction costs, and retained all remaining shares of common stock acquired upon exercise. F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $55.58 to $56.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $56.59 to $57.59. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $57.60 to $58.59. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F5 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $58.61 to $59.34. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. | SEC |
| 2026-10-15 | 2026-10-16 | Hoge Stephen | President | $8.6M | S — Open-market sale (scheduled 10b5-1)2 Form 4 footnotesF1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $220.60 to $221.35. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. | SEC |
| 2026-10-14 | 2026-10-16 | Hoge Stephen | President | $8.4M | S — Open-market sale (scheduled 10b5-1)3 Form 4 footnotesF1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $213.03 to $213.91. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $214.05 to $214.37. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. | SEC |
| 2026-02-23 | 2026-02-25 | Hoge Stephen | President | $7.8M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025. | SEC |
| 2026-09-15 | 2026-09-16 | Hoge Stephen | President | $5.9M | S — Open-market sale (scheduled 10b5-1)2 Form 4 footnotesF1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $145.97 to $146.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. | SEC |
| 2026-09-14 | 2026-09-16 | Hoge Stephen | President | $5.8M | S — Open-market sale (scheduled 10b5-1)2 Form 4 footnotesF1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 15, 2026. F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $143.99 to $144.66. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. | SEC |
| 2026-09-10 | 2026-09-14 | Mock James M | Chief Financial Officer | $4.7M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 9, 2026. | SEC |
| 2026-07-15 | 2026-07-16 | Hoge Stephen | President | $3.6M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025. | SEC |
| 2026-06-15 | 2026-06-17 | Hoge Stephen | President | $2.7M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025. | SEC |
| 2026-05-15 | 2026-05-18 | Hoge Stephen | President | $2.6M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025. | SEC |
| 2026-03-02 | 2026-03-03 | Klinger Shannon Thyme | Chief Legal Officer | $726k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF3 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on September 9, 2025. | SEC |
| 2025-12-11 | 2025-12-15 | Afeyan Noubar | Director | $703k | S — Open-market sale Indirect holding, through: By Flagship Pioneering, Inc. Form 4 footnoteF2 The securities are held directly by Flagship Pioneering. Flagship Pioneering is contractually obligated to transfer and/or remit the proceeds of any sale of shares to Flagship Fund IV, L.P. ("Flagship Fund IV"). The reporting person is the CEO and sole stockholder of Flagship Pioneering and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. | SEC |
| 2026-09-01 | 2026-09-03 | Klinger Shannon Thyme | Chief Legal Officer | $486k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on September 9, 2025. | SEC |
| 2026-05-21 | 2026-05-22 | Afeyan Noubar | Director | $434k | S — Open-market sale Indirect holding, through: By Flagship Pioneering, LLC Form 4 footnoteF2 The securities are held directly by Flagship Pioneering. Flagship Pioneering is contractually obligated to transfer and/or remit the proceeds of any sale of shares to Flagship Fund IV, L.P. ("Flagship Fund IV"). The reporting person is the ultimate control person of Flagship Pioneering and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. | SEC |
| 2026-05-01 | 2026-05-04 | Hussain Abbas | Director | $265k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF2 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on September 5, 2025. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. | SEC |
| 2026-06-04 | 2026-06-08 | Klinger Shannon Thyme | Chief Legal Officer | $174k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on September 9, 2025. | SEC |
| 2025-12-09 | 2025-12-11 | Hussain Abbas | Director | $14k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on September 5, 2025. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. | SEC |
| 2026-08-05 | 2026-08-07 | Bancel Stephane | Chief Executive Officer | $9.6M | M — Option exercise (scheduled 10b5-1)Form 4 footnoteF1 The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026. The Reporting Person exercised in full two stock option awards that were scheduled to expire on August 10, 2026. The options would have been forfeited if not exercised prior to their expiration date. In connection with the cashless exercise and hold transaction, the Reporting Person sold 499,246 shares acquired upon exercise solely to cover the exercise price, applicable withholding taxes, and related transaction costs, and retained all remaining shares of common stock acquired upon exercise. | SEC |
| 2025-12-11 | 2025-12-15 | Bancel Stephane | Chief Executive Officer | $7.5M | M — Option exerciseForm 4 footnoteF1 The Reporting Person acquired 688,073 shares of the Issuer's common stock upon the exercise in full of a stock option scheduled to expire on February 23, 2026. The option would have been forfeited if not exercised prior to that date. The Reporting Person paid the full exercise price of $7,499,995.70 ($10.90 per share) and applicable withholding taxes of $5,998,279.76 in cash, for a total cash amount of $13,498,275.46. No shares of the Issuer were sold or withheld in connection with the exercise. | SEC |
| 2026-08-06 | 2026-08-07 | Bancel Stephane | Chief Executive Officer | $4.8M | M — Option exercise (scheduled 10b5-1)Form 4 footnoteF1 The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026. The Reporting Person exercised in full two stock option awards that were scheduled to expire on August 10, 2026. The options would have been forfeited if not exercised prior to their expiration date. In connection with the cashless exercise and hold transaction, the Reporting Person sold 499,246 shares acquired upon exercise solely to cover the exercise price, applicable withholding taxes, and related transaction costs, and retained all remaining shares of common stock acquired upon exercise. | SEC |
The period balance: money in, money out
In the Form 4 filings submitted between Aug 29, 2025 and Oct 16, 2026 there is not one open-market purchase of Moderna, Inc.: 17 sales worth $81.6M and zero dollars bought.
Only codes P and S count, where an insider puts in or takes out their own money. A selling balance like Moderna, Inc.'s is the norm in the S&P 500, where much of the pay comes as stock. It is not a recommendation to buy or sell: it is what was filed.
Every transaction, code by code
| Code | What it means | Trades | Reported amount |
|---|---|---|---|
| M | Option exercise | 73 | $33.5M |
| F | Tax withholding (shares surrendered for taxes) | 54 | $8.1M |
| S | Open-market sale | 17 | $81.6M |
| A | Grant or award | 4 | $0 |
| Total | Everything filed in the period | 148 | $123.2M |
60 of the 148 rows carry no usable amount on the Form 4: they count as trades and add $0. The code labels come from the SEC index.
Who has traded
Over the 15 months of history, 11 distinct people or entities have filed Moderna, Inc. transactions: none bought on the open market and 6 sold. Counted by CIK, the fixed number the SEC gives each filer, and not by name, which each filer types their own way.
Of the 6 who sold on the open market (17 sales in all), the three biggest sellers account for $78.8M of the $81.6M: 97% of the money in three people.
| Filer | Role | Transactions | Bought (count) | Sold (count) | Last filed |
|---|---|---|---|---|---|
| Hoge Stephen | President | 44 | — | $45.4M (8) | 2026-10-16 |
| Bancel Stephane | Chief Executive Officer | 6 | — | $28.7M (1) | 2026-08-07 |
| Mock James M | Chief Financial Officer | 44 | — | $4.7M (1) | 2026-10-07 |
| Klinger Shannon Thyme | Chief Legal Officer | 41 | — | $1.4M (3) | 2026-09-08 |
| Afeyan Noubar | Director | 4 | — | $1.1M (2) | 2026-05-22 |
| Hussain Abbas | Director | 4 | — | $279k (2) | 2026-05-04 |
| Horning Sandra | Director | 1 | — | — | 2026-05-04 |
| Nabel Elizabeth G | Director | 1 | — | — | 2026-05-04 |
Shown here are the 8 who moved the most money, out of 11. The rest are in the full history, one link above. The name links to all their trades, in any company. "Transactions" counts any code; the money, open market only. Role: from their latest filing.
Month by month
By the month the trade was executed, not the month it was filed; months with no trades show zero. The busiest month was Sep 2026: 0 purchases and 4 sales, worth $16.9M. 6 of the 15 months have none.
| Month | Purchases | Amount | Sales | Amount |
|---|---|---|---|---|
| Aug 2025 | 0 | $0 | 0 | $0 |
| Sep 2025 | 0 | $0 | 0 | $0 |
| Oct 2025 | 0 | $0 | 0 | $0 |
| Nov 2025 | 0 | $0 | 0 | $0 |
| Dec 2025 | 0 | $0 | 2 | $717k |
| Jan 2026 | 0 | $0 | 0 | $0 |
| Feb 2026 | 0 | $0 | 1 | $7.8M |
| Mar 2026 | 0 | $0 | 1 | $726k |
| Apr 2026 | 0 | $0 | 0 | $0 |
| May 2026 | 0 | $0 | 3 | $3.3M |
| Jun 2026 | 0 | $0 | 2 | $2.9M |
| Jul 2026 | 0 | $0 | 1 | $3.6M |
| Aug 2026 | 0 | $0 | 1 | $28.7M |
| Sep 2026 | 0 | $0 | 4 | $16.9M |
| Oct 2026 | 0 | $0 | 2 | $17.0M |
The last month may be partial: a Form 4 is filed up to two business days later. The table does not say whether the pattern is good or bad; it says when it happened.
Moderna, Inc. (MRNA) analysis page →
Other Healthcare companies with insider trades
All 500 are listed in the section index →
Which insiders are buying their own company stock →
How to read this data
15 of the 17 sales in the table are flagged as scheduled (10b5-1 plan): signed months ahead and executed automatically, so they say nothing about what the insider thinks today. Moderna has no open-market purchase (code P) in the history, the most common case in the S&P 500: insiders are already paid in stock. The latest filing is from Oct 16, 2026, and a Form 4 arrives up to two business days after the trade.
20 of the 20 rows in the table carry footnotes from the Form 4 itself, folded into the code column and copied verbatim; a row with no footnote means the filing has none.
Guide: Insider buying · all guides
What is behind these trades
The concepts on this page, explained from scratch in the Academy. Free, no account.
- What the efficiency hypothesis says and what it does NOT sayIf an insider's purchase is public and anyone can read it, is there any information left in it? That is the exact question that brings people here.
- Who really moves the market: the types of investorWho sits on the other side of each order, and where a company's own insiders fit among them.
- Supply, demand and price: why it rises and falls constantlyHow a piece of news ends up inside the price, and why the reaction to a filed sale is rarely the one you would expect.
Source: SEC EDGAR Form 4. This is a list of public facts, not financial advice or a recommendation to buy or sell.